Copyright: ©Author(s) 2026.
World J Gastroenterol. May 7, 2026; 32(17): 117544
Published online May 7, 2026. doi: 10.3748/wjg.v32.i17.117544
Published online May 7, 2026. doi: 10.3748/wjg.v32.i17.117544
Table 1 Baseline characteristics of study participants before Helicobacter pylori treatment, n (%)
| Category | Variable | H. pylori-positive | H. pylori-negative | Nominal P value | Adjusted q value |
| Sociodemographic | Age (years) | 60.2 ± 9.2 | 60.3 ± 7.3 | 0.938 | 0.938 |
| Male | 138 (52.7) | 78 (56.5) | 0.604 | 0.672 | |
| Female | 124 (47.3) | 60 (43.5) | 0.604 | 0.672 | |
| Diabetes mellitus | 72 (27.5) | 43 (31.2) | 0.452 | 0.603 | |
| Biochemical | ALT (IU/L), median (interquartile range) | 40.4 (22.6) | 36.3 (28.8) | 0.269 | 0.403 |
| AST (IU/L), median (interquartile range) | 42.7 (23.2) | 37.9 (20.6) | 0.150 | 0.300 | |
| Albumin (g/dL) | 3.5 ± 0.4b | 3.9 ± 0.6 | < 0.001 | < 0.001 | |
| Urea (mg/dL) | 29.3 ± 6.4b | 23.5 ± 4.6 | < 0.001 | < 0.001 | |
| Sodium (mmol/L) | 137.8 ± 2.9b | 135.3 ± 3.5 | < 0.001 | < 0.001 | |
| Potassium (mmol/L) | 4.1 ± 0.9a | 3.8 ± 0.6a | 0.014 | 0.028 | |
| Cholesterol (mg/dL) | 191.0 ± 29.7a | 177.0 ± 35.9a | 0.004 | 0.012 | |
| Triglycerides (mg/dL), median (interquartile range) | 94.6 (58.6) | 87.6 (55.2) | 0.414 | 0.518 | |
| HDL (mg/dL), median (interquartile range) | 43.1 (41.2) | 53.5 (50.2) | 0.118 | 0.236 | |
| LDL (mg/dL), median (interquartile range) | 156.3 (88.9) | 140.6 (81.5) | 0.224 | 0.374 | |
| Random blood sugar (mg/dL), median (interquartile range) | 128.5 (89.2) | 130.1 (92.3) | 0.850 | 0.850 | |
| HbA1c (%) | 6.8 ± 1.2 | 6.9 ± 1.3 | 0.587 | 0.671 | |
| Digestive symptoms (GSRS) | Total GSRS score | 2.9 ± 0.8b | 1.7 ± 0.6 | < 0.001 | < 0.001 |
| Abdominal pain | 90 (34.4)a | 30 (21.7) | 0.012 | 0.024 | |
| Bloating | 60 (22.9) | 20 (14.5) | 0.045 | 0.068 | |
| Nausea | 50 (19.1)a | 10 (7.2) | 0.003 | 0.009 |
- Citation: Semeya AA, Makled WA, Elnagdy MA, Elgamal R, Othman AAA. Helicobacter pylori eradication and the prevention of peptic ulcer bleeding and cardiovascular disease progression in chronic aspirin users. World J Gastroenterol 2026; 32(17): 117544
- URL: https://www.wjgnet.com/1007-9327/full/v32/i17/117544.htm
- DOI: https://dx.doi.org/10.3748/wjg.v32.i17.117544